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ABSTRACT
Exosomes (Exo)-based therapy holds promise for treatment of lethal pancreatic cancer (PC). 
Limited understanding of key factors affecting Exo uptake in PC cells restricts better design of 
Exo-based therapy. This work aims to study the uptake properties of different Exo by PC cells. Exo 
from pancreatic carcinoma, melanoma and non-cancer cell lines were isolated and characterised 
for yield, size, morphology and exosomal marker expression. Isolated Exo were fluorescently 
labelled using a novel in-house developed method based on copper-free click chemistry to 
enable intracellular tracking and uptake quantification in cells. Important factors influencing 
Exo uptake were initially predicted by Design of Experiments (DoE) approach to facilitate sub-
sequent actual experimental investigations. Uptake of all Exo types by PC cells (PANC-1) showed 
time- and dose-dependence as predicted by the DoE model. PANC-1 cell-derived exosomes 
(PANC-1 Exo) showed significantly higher uptake in PANC-1 cells than that of other Exo types 
at the longest incubation time and highest Exo dose. In vivo biodistribution studies in subcuta-
neous tumour-bearing mice similarly showed favoured accumulation of PANC-1 Exo in self-tissue 
(i.e. PANC-1 tumour mass) over the more vascularised melanoma (B16-F10) tumours, suggesting 
intrinsic tropism of PC-derived Exo for their parent cells. This study provides a simple, universal 
and reliable surface modification approach via click chemistry for in vitro and in vivo exosome 
uptake studies and can serve as a basis for a rationalised design approach for pre-clinical Exo 
cancer therapies.
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Introduction
Pancreatic cancer (PC) is one of the most devastating 
cancer, of which its mortality rate is the highest among 
all cancer types owing to long asymptomatic disease 
progression and poor early detection [1,2]. 
Development of promising therapeutic tools is needed 
for the treatment of PC. Recent research interests are 
drawn towards exosomes, which are 50–150 nm multi-
vesicular body-derived extracellular vesicles released by 
various cells and are present in biological fluids or 
in vitro cell culture supernatants [3]. Exosomes possess 
the ability to deliver their cargoes, e.g. proteins, lipids, 
and nucleic acids to distant recipient cells and these 
cargoes can induce changes in recipient cells related to 
regular physiological functioning or pathological 
progression [4]. There are an increasing number of 
reports demonstrating the potential of using exosomes 
as nanocarriers for improved delivery of exogenously 
loaded drug therapeutics as novel treatment strategies 
for PC [5]. For example, exosomes were used to deliver 
siRNA to oncogenic K-RasG12D, a common mutation 
in PC, resulting in suppression of PC and increasing 
overall survival in mice [5]. Curcumin was also 
reported to be delivered by exosomes to PC cells, 
resulting in anti-inflammatory effect and a significant 
reduction of pancreatic adenocarcinoma cell viability 
[1]. It has been reported that exosomes show better 
uptake profiles in mouse models as compared to lipo-
somes, potentially due to the unique set of proteins 
(e.g. various integrins, adhesion proteins and phospha-
tidylserine) present on exosomal membranes which 
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play important roles in facilitating uptake [6,7,8]. 
Certain exosomes were also reported to express 
a transmembrane protein called CD47 which can pro-
tect them from phagocytosis and result in prolonged 
in vivo circulation time [5]. This naturally occurring 
factor, therefore, provides similar advantages to that by 
PEGylation of other synthetic nanoparticles without 
the drawback of reduced cellular uptake associated 
with the latter [9].
Despite various attempts, progress in exosome- 
mediated cancer therapies including PC remained 
slow. This is largely due to the limited understanding 
of exosome-cell interaction. Recipient cells were 
reported to internalise exosomes by a variety of mechan-
isms such as receptor-mediated pathways, macropinocy-
tosis, phagocytosis and membrane fusion [10–13]. 
Various cells have been demonstrated to take up exo-
somes from different cell sources, but to different 
extents [14,15]. Non-biological factors such as incuba-
tion time of cells with exosome and exosome dose were 
reported to affect cellular uptake of exosomes [16,17]. 
Interestingly, it was reported that exosomes potentially 
have tropism towards their cell/tissue of origin [18], and 
that tumour cell lines were reported to show higher 
uptake of tumour-derived exosomes compared to non- 
cancer immortalised cell lines [17]. Preferential uptake 
of tumour-derived exosomes by their parent cells was 
demonstrated in vitro and in vivo in an ovarian cancer 
model [19]. However, a systematic study investigating 
the significance of non-biological factors such as incu-
bation time and exosome dose, as well as the tropism of 
exosomes for their parent cells in PC models is currently 
unavailable.
Fluorescence labelling of exosomes can facilitate the 
investigation of their in vitro and in vivo uptake. Current 
approaches are mostly based on non-covalent fluores-
cence labelling strategies involving the use of lipophilic 
dyes (e.g. PKH26, PKH67, DiI and DiO). Such labelling 
methods are associated with drawbacks such as aggrega-
tion or micelles formation in aqueous solutions, dye 
leakage and non-specific exchange with endogenous tis-
sue membranes [18,20–23]. These result in false-positive 
signals such as non-exosome-associated dye-positive par-
ticles indistinguishable from labelled exosomes, leading 
to data misinterpretations [24]. Therefore, a reliable and 
efficient exosome fluorescent labelling approach is crucial 
for accurate interpretation of the results from their uptake 
studies.
This work aims to study the important factors gov-
erning uptake of exosomes sourced from different cell 
types in in vitro and in vivo PC models for a rational 
selection of unmodified exosomes as nanocarriers for 
delivery of therapeutics to PC. This is facilitated by 
a novel, universal and reliable exosome surface fluor-
escence labelling approach based on copper-free click 
chemistry. Design of Experiments (DoE) was employed 
as a modelling platform to predict the significance of 
multiple parameters (i.e. incubation time, exosome 
dose and exosome-parent cell pairing) and their multi-
factorial interactions in exosome cellular uptake. The 
DoE predictive model was then validated using semi- 
quantitative uptake studies of exosomes from the dif-
ferent cell sources by PC cells in vitro and in vivo.
Materials and methods
Cell culture
B16-F10 (ATCC CRL-6475) and PANC-1 (ATCC 
CRL-1469) cell lines were grown in Advanced RPMI 
1640 media, and HEK-293 cell line (ATCC CRL-1573) 
was grown in MEM media, both supplemented with 
10% exosome-free FBS, 1% Penicillin-Streptomycin 
and 1% GlutaMAXTM (Gibco, Thermo Fisher 
Scientific). HPAC cell line (ATCC CRL-2119) was 
grown in DMEM/F12 (1:1) media, supplemented with 
10% exosome-free FBS and 1% Penicillin- 
Streptomycin. All cells were maintained at 37°C in 
a humidified incubator containing 5% CO2. Exosome- 
depleted FBS was prepared by subjecting FBS to ultra-
centrifugation (Optima XE, Beckman Coulter) at 
100,000 g for 18 h at 4°C. The FBS supernatant post- 
centrifugation was collected and sterile-filtered using 
0.22 µm filters for use in cell culture.
Exosome isolation
Culture supernatants of B16-F10, PANC-1 and HEK- 
293 cells were harvested after 1-week culture in 
CELLine AD1000 bioreactor flasks (WHEATON UK). 
Cells from 4 × T75 flasks (80% confluent) in 15 mL 
medium supplemented with 10% exosome-depleted 
FBS were seeded into the cell compartment of 1 bior-
eactor flask. The medium reservoir compartment of the 
flask was filled with 500 mL of the medium supple-
mented with 10% normal FBS. Culture supernatant or 
conditioned medium (CM) was harvested from the cell 
compartment of the flask on a weekly basis and 
replaced with 15 mL of fresh medium supplemented 
with 10% exosome-depleted FBS. To isolate exosomes, 
cell debris was firstly removed by centrifugation at 
400 × g for 7 min and at 2,000 × g for 15 min at 4°C. 
The supernatant was filtered through a 0.22 µm filter 
(Millipore). Exosomes were then isolated by ultracen-
trifugation onto a sucrose cushion (25% w/w sucrose in 
D2O, density 1.18–1.20 g/mL) at 100,000 × g for 
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90 min at 4°C. Upon completion, the sucrose solution 
layer was collected, washed with PBS, and centrifuged 
at 100,000 × g for 90 min at 4°C. The final pellet 
containing exosomes was resuspended in 200 µL sterile 
PBS and aliquoted before storage at −80°C.
Exosome characterisation
Size distribution and particle concentration of 
exosomes
The size distribution and particle number/concentra-
tion of exosomes were measured by nanoparticle track-
ing analysis (NTA) using a Nanosight LM10 system 
with blue (488 nm) laser (Malvern Instruments, UK). 
Exosomes were diluted in filtered deionised water to 
obtain 20–60 vesicles per field of view for optimal 
tracking. Three videos of 30 s were taken and analysed 
using the NanoSight NTA 3.2 software. The area under 
the histogram for each triplicate measurement was 
averaged and used as one particle concentration mea-
surement. All NTA measurements were done with 
identical system settings for consistency.
Exosomal surface proteins characterisation using 
flow cytometry
Exosome suspension in PBS (40 µL) was mixed with 
10 µL of beads (aldehyde sulphate latex 4% w/v, 
Thermo Fisher Scientific, UK) for 15 min at room 
temperature (RT). PBS only was used as control. 
Bovine serum albumin (BSA, 100 µM, 5 µL, Thermo 
Fisher Scientific, UK) was added into the exosome- 
bead mixture and incubated for 15 min at RT. One 
millilitre of PBS was then added and incubated for 
another 75 min at RT under gentle mixing. The beads 
were pelleted by centrifugation at 580 × g for 5 min. 
After supernatant removal, the pellet was incubated in 
1 mL of 100 mM glycine for 30 min at RT. The beads 
were washed with 1 mL of PBS twice, and resuspended 
in 150 µL of PBS. Exo-bead complex was stained with 
anti-CD9 (clone HI9a (anti-human), clone MZ3 (anti- 
mouse), BioLegend, UK), anti-CD63 (clone TS63 (anti- 
human), clone EPR21151 (anti-mouse), Abcam, UK) 
or anti-CD81 (clone 5A6 (anti-human), clone Eat-2 
(anti-mouse), BioLegend, UK) primary antibo-
dies (anti-human for PANC-1 and HEK-293 exosomes; 
anti-mouse for B16-F10 exosomes) for 45 min at 4°C, 
and then stained with the Cy5-conjugated secondary 
antibody (eBioscience, UK) for 30 min at RT. The 
pellets were washed and resuspended with an appro-
priate volume of 3% FBS/PBS for flow cytometry (BD 
FACSCaliburTM, USA). A total of 50,000 events were 
collected and the mean fluorescence intensity (MFI) 
was recorded. Degree of expression of the markers is 
expressed as the fold increase in MFI values to Exo- 
beads complex stained with the Cy5-conjugated sec-
ondary antibody only.
Protein amount quantification
Protein amounts in exosome and cell lysates were 
quantified using micro BCA and regular BCA kits 
(Thermo Fisher Scientific, UK), respectively, follow-
ing the protocol provided by the supplier. For cell 
lysate preparation, cells were cultured in 75 cm2 
flasks until 80–90% confluent. Cells were then 
detached with trypsin, neutralised with culture 
media and pelleted by spinning at 400 × g for 
5 min. The supernatant was discarded, and the cells 
were washed with PBS twice using the same centri-
fugation conditions as above, before the addition of 
lysis buffer (RIPA buffer with protease inhibitor 
cocktail added) (Merck, UK) to the cell pellet from 
the final spin. The cells were kept on ice for 30 min, 
vortexing every 10 min to ensure maximal lysis. The 
mixture was then subjected to centrifugation at 
20,000 × g for 30 min at 4°C, and the supernatant 
(i.e. the lysate) was collected in fresh microcentrifuge 
tubes, and kept at −80°C until use.
Luminal exosomal protein detection by dot blot
Exosomes and cell lysates were spotted on 
a nitrocellulose membrane (Thermo Fisher 
Scientific, UK) (0.5 µg protein in 40 µL for all sam-
ples – 10 µL at a time, dried under a nitrogen stream 
before addition of the next 10 µL on the same spot). 
The membrane was blocked with 3% milk (w/v) pre-
pared in TBS-T (TBS pH 7.6 containing 0.1% Tween- 
20) for 1 h at RT. The membrane was then incubated 
with primary rabbit anti-human/mouse antibodies: 
anti-Alix (monoclonal, clone 3A9, ab117600, Abcam, 
UK), anti-TSG101 (polyclonal, 14497-1-AP, 
ProteinTech, UK), anti-CANX (polyclonal, 10427- 
2-AP, ProteinTech, UK) and anti-GAPDH (monoclo-
nal, clone 14C10, #2118, Cell Signalling Technology, 
UK) antibodies (1:1000 in 3% milk), overnight at 4°C. 
The membrane was washed three times with TBS-T, 
followed by incubation with goat anti-rabbit second-
ary antibody (polyclonal, ab6721, 1:1000 in 3% milk) 
for 1 h at RT. The membrane was then washed again 
as above, and SuperSignal™ West Femto Maximum 
Sensitivity ECL substrate (Thermo Fisher Scientific, 
UK) was added to the membrane (50 µL per sample 
spot). The membrane was incubated with the sub-
strate for 2 min at RT, and then imaged using the Gel 
Doc™ system (Bio-Rad, USA) under the “Intense 
Bands” setting. The image obtained was analysed 
using the Image Lab™ software (Bio-Rad, USA).
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Morphology characterisation of exosomes
Freshly isolated exosome particles were used for elec-
tron microscopy observation. Scanning electron micro-
scopy (SEM) was performed using FEI Inspect-F 
(Philips, Eindhoven, the Netherlands) equipment oper-
ated at 20 kV. Diluted exosome aliquots were fixed in 
5% glutaraldehyde (Sigma-Aldrich) for 2 h and then 
incubated on the surface of (3-Aminopropyl)triethox-
ysilane(APTES) (Sigma-Aldrich) pre-treated silicon 
wafer for 1 h. The sample was then washed with PBS 
for three times and dehydrated in a series of increasing 
ethanol concentrations (20, 50, 70, 90, 95, 100%). 
Samples were then transferred for critical drying 
(Samdri, Tousimis). The samples were sputter coated 
with gold before SEM scanning.
Transmission electron microscopy (TEM) was per-
formed using Philips CM 12 (FEI Electron Optics, The 
Netherlands) equipped with Tungsten filament and 
a Veleta – 2 k × 2 k side-mounted TEM CCD Camera 
(Olympus, Japan). The accelerating voltage was 80 kV. The 
spot size was set at 2. Objective aperture was used with all 
samples. Diluted exosome aliquots were fixed in 2.5% 
formaldehyde/glutaraldehyde (Sigma-Aldrich) in 0.1 M 
sodium cacodylate (Sigma-Aldrich) buffer, pH 7.4 for 
15 min. Samples were then placed on 300 mesh carbon- 
coated copper grids (Agar Scientific, UK) until air dry. The 
samples were negatively stained with Millipore-filtered 
aqueous uranyl acetate (Agar Scientific, 25% in methanol) 
for 4 min followed by two 50% methanol/H2O wash. After 
air drying, the samples were observed under TEM.
Exosome fluorescence labelling via copper-free 
click chemistry
Exosome suspension (200 µL, 2.8 × 1012 particle/mL) was 
mixed with 1 µL of 10 mg/mL of dibenzylcyclooctyne- 
NHS ester (DBCO-NHS, Lumiprobe) for 1 h in the dark 
at RT. Alexa FluorTM 488 azide (Life Technologies) 
(AF488-azide, 3.8 µL, 5 mg/mL) was then added and 
incubated for 4 h in the dark at RT. The molar ratio of 
exosome/DBCO-NHS/AF488-azide was 1:400:400. 
Unconjugated dye was removed by ultrafiltration using 
Nanosep® 300 K (Pall Life Sciences) or gel filtration using 
Sepharose CL-2B columns. For ultrafiltration, concen-
trated exosomes in the upper compartment of the 
Nanosep®column were resuspended with 200 µL PBS 
and collected in 1.5 mL microcentrifuge tubes after 
three consecutive centrifugations at 14,000 × g for 
5 min at 4°C. For gel filtration, Sepharose® CL-2B 
(Sigma-Aldrich) as the resolving matrix was self-packed 
according to the dimensions of the commercially avail-
able NAP-5™ columns (Thermo Fisher Scientific) and 
optimised such that exosomes will elute in the first 
2 × 500 µL fractions (F1 and F2). Then, 100 µL of labelled 
exosome solution was added to the column, followed by 
elution with 400 µL PBS (Fraction 0) and a series of 
elution with 500 µL PBS per fraction. Fractions 1 and 2 
containing labelled exosomes were collected and stored at 
4°C as a stock solution. Fluorescence intensity (FI) of 
labelled exosome (100 µL) was measured in black- 
walled 96-well plates using a FLUOstar Omega plate 
reader (Ex/Em: 485/520 nm) (BMG Labtechnologies 
GmbH, Germany). FI per exosome particle was calcu-
lated using the following formula:
For ultrafiltration, labelling efficiency was determined by 
measuring the number of resuspended labelled exosomes 
by NTA compared with the number of unlabelled exo-
some stock. For gel filtration, labelling efficiency was 
determined by comparing the number of exosomes in 
Fraction 1 and 2 (1000 µL total) with the number of 
unlabelled exosome stock in 100 µL. The labelling effi-
ciency was used to calculate FI per exosome and the 
number of labelled exosomes in stock solution.
Measurement of fluorescent cells using flow 
cytometry
Cells (30 K) were cultured in Costar® 24-well flat- 
bottom plates and were incubated with labelled exo-
somes according to the chosen incubation times. 
Untreated cells were defined as negative control. 
Following incubation, cells were rinsed with sterile 
PBS, detached by trypsinisation, and resuspended in 
sterile PBS in polystyrene round-bottom tubes 
(CorningTM). Collected cells were analysed by flow 
cytometer (BD FACSCaliburTM, USA) with 
a minimum of 5,000 events acquired per sample. MFI 
was recorded. Degree of uptake by recipient cells was 
expressed in two different ways:
(i) Number of exosomes taken up by recipient cells, 
or Taken-up particle number (N1):
(ii) The percentage uptake (% Uptake):
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where N0 is the initial dose of exosomes incubated with 
the recipient cells. The taken-up particle number N1 
(number of particles taken up by recipient cells) was 
calculated by dividing Delta FI (the difference between 
FI of untreated cells and FI of treated cells) with FI per 
exosome. Uptake efficiency (%Uptake) was expressed 
as   thepercentage of taken up exosome particles from 
the initial dose of exosomes added to the recipient cells.
Design of experiments
Based on preliminary screening of cellular uptake of three 
types of exosomes in four cell lines (B16-F10, PANC-1, 
HPAC, and HEK-293), four factors were selected for 
cellular uptake simulation. These were defined as two 
qualitative factors (exosome type, cell type), and two 
quantitative factors, i.e. (dose of exosomes, incubation 
time). Multi-factor Design of Experiments (D-optimal 
design) was established using MODDE 10.1 software 
(Umetrics, Sweden) to investigate the effects of individual 
or 2-factor interactions on the responses at different 
levels. HPAC and PANC-1 cells were chosen as represen-
tative PC cells, whereas HEK-293 and B16-F10 cells were 
representatives of human non-cancer cells and non- 
human cancer cells, respectively. Based on the matrix of 
experimental design, 38 tests were designed and con-
ducted in triplicate including three of them as centre 
points. Data fitting and calculation of statistical para-
meters (R2, Q2 and reproducibility) were performed by 
multiple linear regression (MLR) method. The experi-
mental design used in this study allowed fitting the data 
with quadratic interaction model. Two responses investi-
gated are the Taken-up particle number, and %Uptake.
Dose-and time-dependent cellular uptake assay
In the case of time-dependency studies, PANC-1 cells 
were seeded in 6-well plates (Corning B.V., 
Netherlands) at a density of 300,000 cells per well over-
night. The three types of labelled exosomes were then 
added at a dose of 2.0 × 1010 particles per well and 
incubated with the cells for 1, 4, 12, and 24 h at 37°C. 
Cells were then washed with warm PBS, fixed with 4% 
paraformaldehyde (PFA, Sigma-Aldrich) in PBS for 
15 min at RT, and rinsed with PBS for three times. The 
cells were resuspended in 100 µL of PBS. Cell images 
(≥2,000 cells; bright field, dark field and fluorescence 
images) were acquired with an Amnis ImageStreamX 
MARK II (ISX) flow cytometer (Merck Millipore, 
Seattle, WA); A 488 nm wavelength excitation laser, at 
a power of 100 mW was used for excitation of the FITC 
fluorophore. Untreated cells were imaged as control. All 
image analysis was done using the Ideas software envir-
onment (Merck Millipore, Seattle, WA).
For dose-dependency studies, PANC-1 cells were 
seeded in Costar® 24-well flat-bottom plates at 
a density of 30,000 cells per well one day in advance. 
Doses of 4 × 109, 1.2 × 1010, 2.0 × 1010, 2.8 × 1010, 
3.6 × 1010 labelled exosomes derived from B16-F10, 
PANC-1 and HEK-293 cells were added to cultured 
PANC-1 cells and incubated for 24 h. The experi-
ments were performed in triplicate. Cells were col-
lected after incubation and analysed by flow 
cytometry.
Confocal microscopy experiment
Cells were seeded at a density of 30,000 per well and 
grown to confluency overnight on glass coverslips in 24- 
well tissue culture dishes (Corning B.V., The 
Netherlands). Labelled exosomes were then added at 
a dose of 2.0 × 1010 particles per well and incubated 
for 1, 4, 12 and 24 h at 37°C. Cells were then washed 
with warm PBS and fixed in 4% PFA in PBS for 15 min 
at RT. For F-actin staining, cells were permeabilised 
with 0.1% Triton X-100 in PBS for 10 min at 4°C. 
After washing with PBS for 2–3 times, the cells were 
stained with methanolic phallotoxin (Alexa Fluor® 568 
phalloidin, 578/600, Thermo Fisher Scientific, UK) for 
20 min at RT according to the supplier’s protocol, 
followed by 2–3 times PBS washing. For nuclear stain-
ing, cells were treated with DAPI (300 nM in PBS, 
Sigma-Aldrich) for 1–5 min protected from light, then 
rinsed three times with PBS. Coverslips were mounted 
with Vectashield anti-fade mounting medium (Vector 
Laboratories Ltd, USA) and sealed with nail polish. 
Images were obtained using a confocal microscope 
(A1 R Si MP Confocal, Nikon, Japan) with a 60× oil 
immersion objective (Nikon, Japan) and fluorescence 
signals were captured via three bandpass filters 
(492 nm SP, 525/50 nm and 575/25 nm appearing in 
blue, green and red, respectively). For acidic organelles 
staining, cells were treated with prewarmed 75 nM 
LysoTracker Red DND-99 (577/590 nm, Thermo 
Fisher Scientific, UK) in fresh medium for 45 min at 
37°C. After washing with PBS for 2–3 times, cells were 
fixed and nuclear stained as described above.
In vivo uptake of the fluorescent PANC-1 exosomes
All in vivo experiments were conducted under the 
authority of project and personal licences granted by 
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the UK Home Office and the UKCCCR Guidelines 
(1998). Male NOD SCID gamma (NSG) immunodefi-
cient mice, 4–6 weeks old, were obtained from Charles 
River (UK). NSG mice bearing subcutaneous human 
pancreatic cancer (PANC-1) or mouse melanoma 
(B16-F10) were prepared to assess the tumour uptake 
of Cy7.5-labelled exosomes. Briefly, mice were 
anesthetised by isoflurane inhalation and injected 
subcutaneously with 5 × 106 PANC-1 cells (100 μL 
in PBS) or 1 × 106 B16-F10 cells (100 μL in PBS) at 
lower flanks using a sterile syringe with a 26-gauge 
needle. When tumours reached desired size (roughly 
10 days after tumour implantation), mice were anaes-
thetized and injected intravenously (i.v.) with 
Cy7.5-Exo (8 × 1011 particles in 200 μL PBS) via a 
tail vein. At 24 h post-injection, the animals were 
perfused with 25 mL heparinised saline (1000 U/L) 
through the left ventricle of the heart to wash out 
residual or loosely bound exosomes in the circulation. 
All the major organs including liver, spleen, kidneys, 
heart, lungs, brain, stomach and intestine were then 
harvested. Excised organs were weighed, and their FI 
was measured using an IVIS Lumina Series III In Vivo 
Imaging System (Perkin-Elmer, UK). Fluorescence 
signals of the images were quantitatively analysed by 
drawing regions of interest around the tissues using 
the Living Image 4.3.1 Service Pack 2 software 
(Perkin-Elmer, USA). The results are expressed as 
total flux per organ (photons/s) or total photons per 
gram tissue (photons/s/g, mean ± SD).
Statistical analysis
Quantitative results were presented as mean ± SD. 
Student’s unpaired t-test was utilised to compare con-
trol samples against experimental samples, using the 
geometric mean of each separate experiment. For mul-
tiple treated groups, statistical significance was exam-
ined using one-way ANOVA. Significance was 
specified as *p < 0.05, **p < 0.01, or ***p < 0.001.
Results
Exosome characterisation
Physicochemical properties of exosomes isolated from 
PANC-1, B16-F10 and HEK-293 cells are summarised 
in Table 1. Size measurements using NTA showed 
exosomes from all cell lines are of ~100 nm in size, 
which fall in the expected exosome size range (30–-
150 nm) [3,11,25] (Figure 1(a)). There are no signifi-
cant differences (ns) in size between the three types of 
exosomes. TEM and SEM analysis of the exosome 
samples revealed the presence of intact vesicular struc-
tures with lipid-bilayer membranes of similar sizes to 
that measured by NTA (Figure 1(b) & Figure S1) [26]. 
NTA measurements of exosome yield showed that exo-
somes from B16-F10 cell have the highest yield 
(1.0 ± 0.3 × 1013 particle/mL), followed by exosomes 
from PANC-1 cell (7.3 ± 0.3 × 1012 particle/mL) and 
HEK-293 cell (7.0 ± 0.2 × 1012 particle/mL). Zeta 
potential values recorded by PANC-1, B16- 
F10 and HEK-293 exosomes were −15.0 ± 1.8, 
−16.0 ± 2.6 and −16.7 ± 1.0 mV, respectively, which 
were not significantly different and comparable with 
other studies [25]. Protein concentrations in PANC-1, 
B16-F10 and HEK-293 exosome samples were 
100.7 ± 9.3, 116.8 ± 9.1 and 84.3 ± 9.8 µg/mL, respec-
tively. Particle:protein (P:P) ratio was used to assess the 
purity of the exosome samples from contaminating 
proteins co-precipitating from conditioned media dur-
ing isolation. For all preparations, P:P ratio of > 
2 × 1010 particle/μg protein was achieved, suggesting 
high purity of the exosome samples [27,28]. The 
expression of canonical tetraspanins CD9, CD81 and 
CD63 was confirmed on all exosome samples by flow 
cytometry (Figure 1(c)). The expression of the “do-not- 
eat-me” marker CD47 was also assessed on all exosome 
samples by flow cytometry. Both PANC-1 and HEK-293 
Exo showed positive CD47 expression, with the former 
showing a significantly higher expression levels. CD47, 
however, was not expressed, if not only negligible, on 
B16-F10 Exo (Figure 1(d), Figure S2(a–c)). All exosome 
Table 1. Physicochemical characterisation of exosomes.
Exosome
Concentration 
(particle/mL) a,d,e Size (mode, nm) a,d,e Zeta potential (mV)b,d,e
Total protein concentration 
(µg/mL)c,d Exosome to protein ratio (particles/µg) a,c
PANC-1 7.3 ± 0.3 × 1012 101.0 ± 5.4 −15.0 ± 1.8 100.7 ± 9.3 7.3 × 1010
B16-F10 1.0 ± 0.3 × 1013 ** 101.0 ± 2.0 −16.0 ± 2.6 116.8 ± 9.1 8.9 × 1010
HEK-293 7.0 ± 0.2 × 1012 107.0 ± 8.2 −16.7 ± 1.0 84.3 ± 9.8 8.3 × 1010
aValues were obtained using nanoparticle tracking analysis (NTA). Exosomes were isolated from 15 mL of supernatants from CELLine AD1000 bioreactor 
flasks. Pellets were resuspended in 0.4 mL PBS prior to NTA measurement. 
bSamples were diluted 10 times with water before measurement by Zetasizer Nano ZS at 25°C. 
cQuantified using micro BCA protein assay. 
dResults are expressed as mean ± SD, where n = 3. 
eOne-way ANOVA was used for statistical analysis (ns: p > 0.05, p* < 0.05, p** < 0.01). 
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Figure 1. Characterisation of PANC-1, B16-F10 and HEK-293 Exosomes (Exo). (a) Size distributions of PANC-1, B16-F10 and HEK-293 Exo 
obtained by Nanoparticle Tracking Analysis (NTA) using a NanoSight LM-10. The histograms indicate a similar size distribution profile for all 
the three exosomes. (b) Morphology characterisation by transmission electron microscopy (TEM) and scanning electron microscopy (SEM). 
Scale bar: 50 nm. (c) Detection of tetraspanins CD9, CD63 and CD81 on exosomes using flow cytometry. Exosomes were coupled to 
aldehyde/sulphate latex beads prior to detection. Exo-beads complex were subsequently stained using a 2-step labelling (anti-CD9, anti- 
CD63 or anti-CD81 1° Ab/Cy5-conjugated 2° Ab). Degree of expression of the markers are expressed as the fold increase in mean fluorescence 
intensity (MFI) values to Exo-beads complex stained with Cy5-conjugated 2° Ab, where an MFI ratio of 2 was set as the threshold for positive 
expression. (d) Detection of “do-not-eat-me” marker CD47 on PANC-1, B16-F10 and HEK-293 Exo. A MFI ratio of 2 was set as the threshold for 
positive expression. Values are expressed as mean ± SD (n = 3). Statistical analysis were only conducted on human exosomes. *p < 0.05, 
***p < 0.001, ns: No significance. (e) Dot blots for detection of luminal exosomal markers. Equal amounts of protein (0.5 μg in 40 μL) from the 
Exo and cell lysate samples for each cell line were spotted on nitrocellulose membranes. The membranes were then blocked with 3% milk, 
and stained using a 2-step labelling (anti-Alix, anti-TSG101 or anti-CANX 1° Ab/HRP-conjugated 2° Ab).
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samples were found to be enriched for the expression of 
endosomal sorting complexes required for transport 
(ESCRT)-related proteins Alix and TSG101 as compared 
to the lysates of their cell of origin. Though Calnexin 
(CANX-an endoplasmic reticulum-associated protein) 
was slightly positive for exosomes from the B16-F10 
and PANC-1 lines, it was much less enriched for each 
exosome compared to their cell lysate. As outlined in the 
MISEV2018 guidelines [29], this result could further con-
firm their endosomal origin and suggest minimal con-
tamination of non-exosomal vesicles in the samples 
(Figure 1(e)). All exosome samples were also enriched 
for the expression of the cytosolic protein GAPDH, which 
is expected for certain cytosolic enzymes, and indicates 
the isolated exosomes as lipid bilayer structures with 
cytoplasmic material enclosed [29] (Figure S2(d,e)). In 
summary, exosome samples prepared in this study are of 
high yield and purity with regard to contaminating pro-
teins from culture media and non-exosomal vesicles.
Fluorescence labelling of exosomes via click 
chemistry
Fluorescence labelling was performed using a two-step 
labelling reaction (Figure 2(a)). The primary amine 
groups of lysine residues on exosomal surface proteins 
were firstly reacted with N-hydroxysuccinimidyl (NHS) 
group of DBCO in an aqueous environment. The 
alkyne group of DBCO was then coupled to the azide- 
functionalised AlexaFluor®488 (AF488) dye by copper- 
free click reaction. Three labelling protocols were 
compared (Figure S3), and the highest labelling yield 
was obtained when exosomes were first conjugated with 
DBCO-NHS for 1 h at RT and then immediately reacted 
with AF488-azide for 4 h at RT. This labelling protocol 
was used throughout the study.
To ensure complete removal of the unconjugated 
dye, size-exclusion chromatography (Sepharose® CL- 
2B column) and centrifugal ultrafiltration (Nanosep® 
300 K) were compared for post-labelling purification 
(Table 2, Figure S4). The former resulted in ~8 times 
higher exosomal recovery (~78%), hence was chosen as 
the preferred purification method. Labelled exosomes 
eluted in the first 2 fractions as confirmed by spectro-
fluorimetry, NTA measurements and flow cytometry 
(Figure 2(b-d)). Higher FI was recorded at equimolar 
concentrations for B16-F10 exosomes (~4000 arbitrary 
unit per 100 µL of exosome dispersions) than PANC-1 
and HEK-293 exosomes (~2000 arbitrary unit per 
100 µL of exosome dispersions) (Figure S5). This trans-
lates into a higher dye per exosome molar ratios for 
B16-F10 exosome (~10) compared to that of PANC-1 
Figure 2. Clickable surface fluorescence labelling of exosomes and their characterisation. (a) Scheme of the fluorescence labelling 
method of exosome surface using copper-free click chemistry with AlexaFlour®488 (AF488)-azide. (b) Elution profiles (fractions 0–8 
(F0–F8)) of labelled Exo or free dye using gel filtration with CL-2B column for purification. (c) NTA analysis of all the fractions from 
elution of both free dye and labelled Exo. Labelled Exo are collected from F1–F2. (d) Labelling confirmation by flow cytometry 
analysis of labelled Exo. Labelled and unlabelled Exo were conjugated to latex microbeads prior to analysis under the FL1 channel 
for detection of AF488 signals.
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and HEK-293 exosomes (~6), which potentially reflect 
the difference in availability of surface lysine groups on 
each exosome surface.
Next, the stability of the labelled exosomes was 
assessed. The FIremained unchanged at 4°C storage 
for up to 3 months (Figure S5(a–b)). No significant 
differences in size, FI and zeta potential between naïve, 
freshly labelled or 3-month stored exosomes were 
observed (Figure S5, Table S1). Overall, this suggests 
that the copper-free click chemistry-based reaction 
allows fluorescent labelling of exosomes without alter-
ing their physicochemical stability and is, therefore, 
suitable for use in tracking the exosomes in vitro and 
in vivo.
Design of experiment-driven experimental design 
and predictive model
Design of Experiments (DoE) is an experimental design 
tool for optimisation studies and prediction of factor– 
factor interactions in a multiple-variable study based on 
mathematical modelling. Exosome uptake in cells is 
a complex phenomenon which involves multiple factors, 
and that the interaction between the different factors 
might also contribute differently to the uptake properties. 
Hence, the use of a powerful tool like DoE can be 
employed for the optimisation of such extensive experi-
ments. The results from DoE modelling can also be used 
to predict the significance of the factor(s) studied. In this 
study, four recipient cell lines (PANC-1 and HPAC – 
human pancreatic carcinoma; B16-F10- murine mela-
noma; HEK-293- human non-cancer), three exosome 
types (PANC-1, B16-F10, HEK-293), four incubation 
time points (1, 4, 12, 24 h) and four exosome doses (0.4, 
1.2, 1.8, 3.0 × 1010 particles) were selected as the four 
“variables” in a D-optimal DoE study to determine the 
extent of each effect independently as well as their inter-
actions in influencing intracellular uptake of exosomes 
[30] (Figure 3(a)). Responses in this prediction model 
were the “Taken-up particle number” and “%Uptake”. 
Based on the DoE design, a total of 38 runs instead of 
114 experiments were performed in random order using 
AF488-labelled exosomes obtained from the previous 
section and the results were uploaded back into the soft-
ware to establish the predictive model. MLR regression 
analysis showed a good prediction quality with both R2 
(Goodness of fit) and Q2 (Goodness of prediction) values 
of > 0.5, and the absolute difference between these two is 
<0.2 [30] (Figure 3(b)). The predictive model showed that 
both incubation time and exosome dose as important 
factors governing uptake, given by the highly positive 
coefficients for Taken up particle number (Figure S6, 
Table S2). The predictive model also showed that exo-
some-parent cell combination as an important factor for 
uptake of exosomes by pancreatic carcinoma cell lines, 
given by the positive coefficients recorded by PANC-1 
and HPAC cells when paired with PANC-1 exosomes, 
but not when both cell lines were paired with exosomes 
derived from other cell sources (Figure S6, Table S2). 
A similar pattern was observed from the predictive 
model for B16-F10 cells - B16-F10 Exo pair indicating 
similar importance of this variable in influencing uptake. 
For HEK-293 cells, positive coefficients were observed 
when paired with both HEK-293 and PANC-1 Exo, sug-
gesting a lower significance of exosome source in influen-
cing cellular uptake. As this study aims to focus on 
determining important factors governing exosome 
uptake by PC cells, PANC-1 cell line was chosen as the 
model PC recipient for more in-depth subsequent 
analysis.
Contour plots obtained from the predictive DoE 
model showed both incubation time and exosome 
dose have a positive effect on the Taken-up particle 
number response for all exosome types in PANC-1 
cells (Figure 3(c), left panel). The parameters in the 
white boxes of contour plots are the predicted Taken- 
up particle number at a certain time and dose, as 
generated by the software after modelling. This sug-
gests that PANC-1 cells take up more exosomes regard-
less of their origin with increasing time or dose. The 
contour plots also indicate that the resultant effect of 
time and dose becomes more significant (red banding) 
at longer time point and higher dose range. Exosome 
source, however, showed a different effect to this mea-
sure of response. PANC-1 cells could take up more 
than 8 × 108 PANC-1 Exo at the highest dose 












Dye molecule per 
exosome b,cExosome recovery (%)a,c
PANC-1 13.4 ± 2.7 78.8 ± 1.5 5.3 ± 0.2 6.4 ± 1.2
B16-F10 11.4 ± 2.3 79.4 ± 1.6 9.8 ± 0.5 9.5 ± 0.8
HEK-293 9.3 ± 1.7 77.0 ± 1.5 5.2 ± 0.1 6.1 ± 1.4
aExosome recovery was calculated as the percentage of particles recovered 
from the original exosome number used. For ultrafiltration, the recovered 
particle number was obtained from NTA measurement of the retentate in 
the NanoSep filter column. For the gel filtration, the recovered number 
was obtained from NTA measurement of all fractions collected after 
elution. 
bCalculations were based on gel filtration purification method. The labelling 
efficiency was calculated as the percentage of fluorescence signals in 
Fraction 1 and 2 (1,000 µL total) of total fluorescence intensity of 
exosome stock (100 µL) before purification. The labelling efficiency was 
used to calculate AF488 per Exo molar ratio. 
cAll measurements were carried out in triplicate and values are shown as 
mean ± SD. 
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Figure 3. Design of experiments (DoE)-driven modelling of exosome cellular uptake. D-optimal design was established to combine 
four varied factors (exosome type, cell type, time and dose) at different levels to investigate the effects of individual factor or 
2-factor interactions on the exosome cellular uptake. (a) Input information for establishing D-optimal Design using MODDE software. 
(b) Assessing the prediction power of the model in a plot of predicted vs. observed (with 1–1 line in black dashed line). Statistical 
parameters of the DoE model for Taken-up particle number and %Uptake modelling are summarised below the fitted data. (c) 
Contour plots relating the effect of incubation time and Exo dose on Taken-up particle number (left) and %Uptake (right) for PANC- 
1, B16-F10, HEK-293 Exo in PANC-1 cells. The red and darkest blue colour indicate the highest and lowest responses, respectively.
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(3 × 1010) at 24 h. This was higher than that of either 
B16-F10 or HEK-293 Exo, both of which are predicted 
to be 7 × 108 at highest dose. This observation is 
similar for other incubation time and exosome dose 
tested, suggesting that uptake of PANC-1 Exo was 
favoured by PANC-1 cells over other exosome types 
at any given dose or incubation time.
On the other hand, the contour plots showed that % 
Uptake of exosomes in PANC-1 cells increased with 
incubation time but decreased with increasing exosome 
dose, regardless of exosome sources (Figure 3(c), right 
panel). The parameters in the white boxes of contour 
plots are the predicted %Uptake at a certain time and 
dose, as generated by the software after modelling. 
Higher %Uptake was obtained at the lower end of the 
dose range. This is due to the smaller change in taken- 
up number (numerator for %Uptake) than the starting 
amount of exosome particle number (denominator for 
%Uptake). Interestingly, by comparison at 24 h and 
5 × 109 particle dose, PANC-1 exosomes recorded 7% 
uptake in PANC-1 cells, which is higher than the other 
two exosomes which only accounted for 4–5% uptake, 
respectively. Again, DoE modelling data suggest that 
PANC-1 Exo has a higher extent of uptake in PANC-1 
cells at a given time or dose than other types of exo-
somes used in the model.
Dose- and time-dependent cellular uptake of 
exosomes
Following the predictive modelling by DoE, the effects of 
single variables, namely, incubation time and exosome 
dose on the uptake of B16-F10, PANC-1 and HEK-293 
exosomes in PANC-1cells were experimentally investi-
gated. Effect of incubation time was studied first. All 
exosome types were fluorescently labelled with AF488 
using the click chemistry-based approach, and incubated 
with PANC-1 cells at a dose of 2 × 1010 particles for 1, 4, 
12and 24 h, respectively. Uptake in PC cells was quanti-
fied using imaging flow cytometry. Quantification of 
exosomes was based on image analysis in two different 
channels: bright field (BF, optical transmission) and 
fluorescence (AF488). Examples of the two image sets 
for four typical PANC-1 cells are shown in Figure S7. 
The morphology of fixed PANC-1 cells seen in the BF 
channel was different than that when they were adherent 
condition since they are now in suspension. 
Quantification of exosome uptake in PANC-1 cells was 
expressed as the MFI per cell in the AF488 channel. 
Values were normalised to account for initial differences 
in sample fluorescence intensities. Uptake of B16-F10 and 
HEK-293 Exoshowed a steady increase with incubation 
time from 1 to 24 h (Figure 4(a)). Uptake of PANC-1 
exosomes also increased from 1 to 12 h but did not 
further increase at 24 h. At earlier time points such as 1 
and 4 h, PANC-1 Exo showed no difference in uptake 
than that of HEK-293 Exo (p > 0.05), while at later time 
points (12 and 24 h), uptake of PANC-1 Exo was signifi-
cantly higher than that of the latter (p < 0.001). All three 
exosome types showed no adverse effect on PANC-1 cell 
viability at 24 h post-incubation (Figure S8). This suggests 
that incubation time is a significant factor that influences 
exosome uptake by PANC-1 cells, and that the cells 
showed a preferential uptake of their “daughter” 
Figure 4. Effect of incubation time and exosome dose on 
in vitro exosome uptake in PANC-1 cells by imaging flow 
cytometry. (a) Time-dependent uptake profile of the three 
exosome types in PANC-1 cells. Each cell simultaneously 
imaged using the Imagestream Cytometer under the bright 
field and fluorescence (AF488) channels after incubation with 
labelled Exo for 1, 4, 12 and 24 h at a fixed dose of 2.0 × 1010 
particles (sub-saturation level). Uptake was measured as the 
mean AF488 signal per cell, normalised according to the dif-
ference in labelling efficiency of the three exosomes. The error 
bars represent the s.e.m. (n > 2000 for all data). (b) Dose- 
dependent uptake profiles of the three exosome types in 
PANC-1 cells. PANC-1 cells were treated with each exosome 
at a dose of 4 × 109, 1.2 × 1010, 2.0 × 1010, 2.8 × 1010, 
3.6 × 1010 particles for 24 h. Uptake was measured as the 
taken-up particle number per cell. Values are presented as 
mean ± SD (n = 3). Statistical analysis was done for the two 
longest incubation times in (a), and the highest dose for (b).
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exosomes over other exosome types at longer incubation 
times e.g. 12 and 24 h.
Next, the effect of exosome dose was investigated. 
PANC-1 cells were incubated with each exosome type 
at a dose of 4 × 109, 1.2 × 1010, 2.0 × 1010, 2.8 × 1010, 
3.6 × 1010 particles for 24 h. The dose range was 
selected based on the DoE modelling data with an 
extension of the highest dose to 3.6 × 1010 particles, 
to study the effect of very high exosome doses on their 
uptake by PANC-1 cells. Their uptake was similarly 
assessed by imaging flow cytometry and was expressed 
as the Taken-up particle number per cell. Uptake of 
PANC-1 Exo and B16-F10 Exo showed a steady 
increase with increasing exosome dose, but that of 
HEK-293 Exo did not show further increase in uptake 
by PANC-1 cells beyond the dose of 2.8 × 1010 particles 
(Figure 4(b)). Uptake of PANC-1 was only significantly 
higher (p < 0.001) than the other two exosome types at 
the highest dose (3.6 × 1010 particles). This suggests 
that exosome dose is also an important factor govern-
ing exosome uptake by PANC-1 cells, and that the cells 
only showed a preferential uptake of their “daughter” 
exosomes at high doses. In summary, the imaging flow 
cytometry data validated the importance of incubation 
time and exosome dose in driving substantial exosome 
uptake by PANC-1 cells as predicted by DoE model-
ling, and that the selective uptake of PANC-1 Exo by 
their parent cell was only apparent at longer incubation 
time and higher exosome dose.
Spatial distribution of exosomes internalised in PC 
cells
Intracellular distribution of exosomes in PANC-1 cells 
at various time points (1, 4, 12 and 24 h) was studied 
using confocal laser scanning microscopy (CLSM). 
A median dose range of 2.0 × 1010 particles per well 
was used as the aim of CLSM study was to understand 
the intracellular distribution of exosomes, and not to 
compare the extent of their uptake. The nuclei were 
counter-stained with DAPI (blue), F-actin was stained 
with AF568 phalloidin (red) and the exosomes were 
labelled with AF488 (green) (Figure 5 and Figure S9). 
PANC-1 Exo were observed to be bound and interna-
lised into the cytoplasm of PANC-1 cells in a time- 
dependent manner (Figure 5(a), left panel). To obtain 
more information on the spatial distribution of inter-
nalised exosomes, the acidic organelles of PANC-1 cells 
(e.g. lysosomes and late endosomes) were stained with 
LysoTracker Red (red) in a separate experiment. The 
yellow signals denote signal overlap i.e. accumulation 
of exosomes (green) in cellular acidic organelles (red), 
and were observed to be more pronounced at 24 h 
(Figure 5(a), right panel). Similarly using F-actin stain-
ing approach, B16-F10 and HEK-293 Exo also showed 
time-dependent uptake (Figure 5b and Figure S9). 
These data indicate that all three exosomes types were 
internalised into the cells and that this click chemistry- 
based surface labelling approach employed is reliable 
for in vitro tracking of exosomes.
Substantial accumulation of PC-derived exosomes 
in pancreatic tumour xenografts after intravenous 
administration
Following encouraging in vitro results suggesting the 
potential favoured uptake of PANC-1 Exo by their par-
ent cells, uptake studies of PANC-1 Exo by self-tissue 
were carried out in PANC-1 tumour-bearing mice to 
determine if such preferential uptake is still apparent 
in vivo when a high dose is administered after 24 h. 
PANC-1 Exo was labelled with Cy7.5 dye using the in- 
house click chemistry-based labelling and administered 
intravenously into the mice (8 × 1011 particles/animal). 
Whole body imaging carried out at 30 min, 4 h and 24 h 
post-injection showed a significantly different biodistri-
bution pattern between the free Cy7.5 dye (control) and 
Cy7.5-labelled PANC-1 Exo, confirming successful and 
stable exosome labelling (Figure 6(a)). This was sup-
ported by the ex vivo imaging and normalised tissue 
fluorescence quantification at 24 h where significantly 
higher liver accumulation was observed in mice admi-
nistered with labelled Exo as compared to that with free 
dye, which is expected for spherical nanoparticles in the 
range of 100–200 nm in size (Figure 6(b,c)). The semi- 
quantitative biodistribution analysis showed that PANC- 
1 Exo recorded the highest accumulation in the liver and 
spleen, followed by the lungs and kidneys at 24 h post- 
injection, which was comparable to other studies (Figure 
6(c)). Interestingly, substantial accumulation of PANC-1 
Exo was observed in self-tissue (i.e. PANC-1 tumour 
mass), and was significantly higher than the signals 
obtained in the tumours of mice administered with 
free dye, again confirming that fluorescence observed 
in the tumours was indeed from labelled PANC-1 Exo. 
To discern whether uptake of PANC-1 Exo in PANC-1 
tumours in vivo is enhanced permeability and retention 
(EPR)-dependent or self-tissue tropism, Cy7.5-labelled 
Exo was intravenously administered (also 8 × 1011 par-
ticles/animal) in mice bearing the more vascularised 
B16-F10 subcutaneous tumours. In this tumour model, 
PANC-1 Exo showed a similar biodistribution in general 
with predominant accumulation in the liver, spleen, 
lungs and kidneys (Figure 6(d)). Whole body and ex 
vivo imaging of data for PANC-1 Exo in B16-F10- 
bearing mice are shown in Figure S10. However, 
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PANC-1 Exo showed a much lower accumulation in 
B16-F10 tumours, and that the values were significantly 
lower than that in PANC-1 tumours despite the former 
being more vascularised (Figure 6(e)). In summary, 
PANC-1 Exo showed substantial accumulation in their 
self-tissue in vivo when administered at a high dose at 
24 h post-administration and that the accumulation was 
reliant on self-tissue tropism, which was consistent with 
Figure 5. Spatial distribution analysis of Exo in PANC-1 cells by confocal laser scanning microscopy (CLSM). PANC-1 cells were 
seeded at 30 K per well in a 24-well plate overnight. Cells were then fixed, nuclei were counter-stained with DAPI (blue), F-actin 
were stained with AF568 phalloidin (red). (a) PANC-1 cells incubated with AF488-labelled PANC-1 Exo (green) at 2.0 × 1010 particles 
per well for 1, 4, 12 and 24 h at 37°C. In a separate experiment, acidic organelles (e.g. lysosomes, late endosomes) were stained with 
LysoTracker Red DND-99 (577/590 nm) (red). (b) PANC-1 cells incubated with B16-F10 Exo (left) or HEK-293 Exo (right) at 2.0 × 1010 
particles per well for 24 h at 37°C. Scale bar: 20 µm.
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Figure 6. In vivo organ biodistribution profile of PANC-1 Exo in tumour-bearing NSG mice. Mice were inoculated subcutaneously 
with PANC-1 cells or B16–F10 cells in bilateral flanks (two tumours per mouse). Animals were intravenously injected with 200 µL 
containing PANC-1 Exo-Cy7.5 (approximately 8 × 1011 particles and 8.3 pmol of dye), Cy7.5 (approximately 8.3 pmol) or saline. 
Animals were killed at 24 h post-injection and the organs were excised for analysis. (a) Whole body live imaging, (b) ex vivo imaging 
and (c) organ biodistribution profiles of PANC-1 Exo in PANC-1 tumour-bearing mice. (d) Organ biodistribution profiles of PANC-1 
Exo in B16–F10 tumour-bearing mice. For (c) and (d), Inset: zoomed-in tumour accumulation profile of PANC-1 Exo. (e) Comparison 
of PANC-1 Exo accumulation in PANC-1 vs B16–F10 tumours. Values were normalised to organ weight and expressed as mean ± SD 
(n = 3). Statistical analysis was done on tumour accumulation values. (ns: no significance, **p < 0.01, ***p < 0.001).
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the in vitro uptake studies. This also validated the relia-
bility of the click chemistry labelling approach for 
in vivo exosome tracking and quantification.
Discussion
In order to be used in a pre-clinical and clinical setting, 
a streamlined exosome isolation platform is highly 
needed [31]. In this study, ultracentrifugation onto 
a sucrose cushion was used to isolate exosomes from 
cell culture supernatant or CM, after prior removal of 
cell debris using differential centrifugations and larger 
vesicles by passing the CM through a 0.22 µm filter. 
This protocol can produce high-quality exosomes, as 
characterised and proved in the downstream applica-
tions such as labelling and uptake studies. Nevertheless, 
it is not suitable for isolating extracellular vesicles 
(EVs) from large volumes which are required in clinical 
settings [31]. A more practical approach, i.e. dealing 
with large volumes yet yield pure EVs is still required 
for isolating exosomes directly from CM, as well as 
from biological fluids in clinical settings.
In this study, presence of CD9, CD63 and CD81 on 
exosomes was confirmed by flow cytometry. Dot blot, 
however, was used for the verification of the presence 
or absence of luminal exosomal markers (Alix, 
TSG101, CANX, and GAPDH). The MISEV 2018 sta-
ted by the International Society for Extracellular 
Vesicles (ISEV) did not exclude dot-blot for protein 
analysis in EVs [29]. It is worth emphasising that 
Western Blotting is a more suitable method than dot 
blot to verify the exact molecular weight of the marker 
protein bands and will be advisable to use in subse-
quent studies instead of dot blot. In our study, we took 
care to block the nitrocellulose membranes using an 
optimised blocking buffer (3% milk) to minimise the 
non-specific binding from both primary and secondary 
antibodies.
As described earlier, fluorescence labelling of exo-
somes commonly done using lipophilic dyes is asso-
ciated with various drawbacks that can lead to major 
result misinterpretations. The click-chemistry surface 
labelling approach proposed in this study is able to 
overcome such drawbacks, while still providing good 
labelling stability (in vivo and 3 months post-labelling 
at 4°C) and maintenance of exosomal integrity post- 
labelling (Figure S5) that can ensure reliable interpreta-
tion of subsequent results. It was also mentioned earlier 
that the unique array of transmembrane proteins 
expressed on exosomes play important roles in their 
intracellular uptake, and so the covalent attachment of 
the initial NHS-DBCO linker bears the risk of disrupt-
ing important binding epitopes of these exosomal 
proteins and therefore affecting cellular uptake of the 
exosomes in vitro and in vivo. Previous work using 
a similar approach for membrane radiolabelling of 
exosomes showed that the initial NHS-amine reaction 
resulted in only minimal disruption of exosomal sur-
face protein epitopes, again ensuring the reliability in 
the uptake results obtained from studies using this 
labelling approach [32]. Although use of nuclear mod-
ality for exosome imaging and uptake quantification 
will offer more robust and accurate quantitative results 
due to limitations associated with the optical modality 
such as 2D acquisition of signals and variable tissue 
penetration depth of fluorescent signals [32], access to 
nuclear-based techniques and equipments is often lim-
ited in the majority of research labs. Hence, fluores-
cent-based imaging and quantification of exosome 
uptake in vitro and in vivo remain a relevant and 
more feasible technique. The surface exosome fluores-
cence labelling approach developed in this study pro-
vides a great tool to ensure comparability and 
reliability of results obtained from such studies.
Click chemistry has been previously reported for 
labelling both exosomes [33,34] and their parent cell 
lines [35]. For example, a facile metabolic incorpora-
tion of azide-labelled glycan on exosomes was devel-
oped, of which the azide-functionalised exosomes are 
then labelled using bio-orthogonal copper-free click 
chemistry for tracking. This approach requires prior 
modification of the parent cells (i.e. feeding the cells 
with tetra-acetylated N-azidoacetyl-D-mannosamine 
for the metabolic incorporation) from which the exo-
somes are derived from, and therefore will not be 
applicable to exosomes derived from biological fluids. 
In comparison, our proposed surface fluorescence 
labelling approach relies on covalent conjugation of 
the NHS-DBCO linker onto primary amines on lysine 
residues of exosomal transmembrane proteins. Lysine 
residues are found to be three times more abundant 
than cysteine residues in living organisms, and so are 
ideal sites for bioconjugation [36]. The surface labelling 
approach proposed in this study is, therefore, 
a universal method that can be applied for labelling 
any exosomes, regardless if they are sourced from cell 
cultures or biological fluids. The reaction between pri-
mary amines with active esters such as 
N-hydroxysuccinimide (NHS) used in this study or 
sulpho-NHS esters to form stable amide bonds, as 
well as the copper-free DBCO-azide click reaction 
occurs rapidly in aqueous solutions at physiological 
pH [34,36,37], thus making this labelling approach 
ideal in terms of only requiring simple and mild reac-
tions without the risk of damaging the exosomes. The 
click chemistry-based fluorescence labelling of 
JOURNAL OF EXTRACELLULAR VESICLES 15
exosomes used in this study also showed about 10-fold 
higher labelling efficiency compared to directly conju-
gating AF488-NHS to exosomes in our previous work 
[32]. A short aliphatic carbon chain links the DBCO to 
the NHS groups in this bifunctional molecule, acting 
like a spacer between these two moieties. This spacer, 
together with the much smaller DBCO moiety poten-
tially minimise steric hindrance for the NHS moiety on 
this molecule to access available amine groups which 
might be buried deeper within the extraluminal 
domains of exosomal transmembrane proteins, thereby 
increasing the rate of the DBCO conjugation to the 
exosome surface and therefore labelling efficiency as 
compared to that of the NHS moiety directly attached 
to a bulkier dye molecule e.g. AF488. A slight outward 
extension away of the DBCO moiety from exosome 
surface by the aliphatic chain spacer also potentially 
minimises similar steric hindrance issue in its subse-
quent reaction with the azide-functionalised bulky dye 
molecule, again contributing towards higher labelling 
efficiency. The primary step of DBCO conjugation to 
exosomal surface also offers versatility for this 
approach to be used for other applications such as 
radiolabelling or other exosome surface functionalisa-
tion by varying the azide-functionalised molecules 
reacted with the conjugated DBCO (e.g. azide-NOTA 
for radiolabelling).
The latest statement from ISEV community high-
lighted the need for a quantitative understanding of 
exosome uptake by cells [29]. Factors determining the 
degree of exosome uptake by recipient cells are yet to 
be properly outlined. To the best of our knowledge, 
this is the first study to use DoE for the prediction of 
single or multifactor interaction in parameters that 
potentially influence cellular uptake of exosomes. Use 
of DoE in this study enabled a more rational experi-
mental design, where the number of relevant experi-
ments required was reduced from 114 to 38 (3 
exosomes, 4 cell lines, 4 time points and 4 doses). 
The DoE model predicted incubation time and exo-
some dose as significant factors affecting uptake of all 
exosome types used in this study, and that both factors 
can contribute synergistically towards exosome uptake. 
This was validated by the actual in vitro uptake studies, 
demonstrating the reliability of DoE modelling as 
a tool for designing multivariable optimisation studies. 
DoE did not generate an uptake profile (curve) for each 
of the investigated exosomes, but DoE did predict that 
PANC-1 Exo showed the highest uptake at the high 
doses. For example, PANC-1 cells could take up more 
than 8 × 108 PANC-1 Exo at the highest dose (3 × 1010) 
at 24 h. This was higher than that of either B16-F10 or 
HEK-293 Exo, both of which were predicted to take up 
7 × 108 particles at the highest dose. Interestingly, the 
DoE model also predicted that exosome-parent cell 
pairing as an important factor in influencing exosome 
uptake a PC context. This was also validated in the 
actual in vitro uptake studies, but such favoured accu-
mulation of PC-derived exosomes by their parent cells 
was only apparent at higher exosome dose and longer 
incubation time. It was reported that smaller exosomes 
are taken up more efficiently by cells [38]. No signifi-
cant differences in size or charge were found between 
the three types of exosomes used in our study 
(p > 0.05) so it is unlikely that differences in uptake 
profiles are size- or charge-dependent. This suggests 
that PC cells show cell-specific preference towards 
internalising self-exosomes, which was also observed 
in other contexts such as in ovarian cancer models 
[19]. As indicated by in vitro exosome uptake study, 
the difference in uptake kinetics could be related to 
different uptake mechanisms. Many studies supported 
the hypothesis that exosomes are primarily taken up by 
receptor-mediated endocytosis [16,21,39,40]. We 
hypothesise that different exosomes were taken up by 
PC cells through different pathways. The main uptake 
pathway of HEK-293 Exo in PANC-1 cells could be 
receptor-mediated, as suggested by the saturable uptake 
profile of HEK-293 Exo potentially due to the limited 
availability of free surface receptors on PC cell mem-
brane at high exosome dose, as receptor-mediated 
endocytosis requires specific interactions between the 
ligands and the receptors on the recipient cells. B16- 
F10 and PANC-1 Exo could have exploited multiple 
endocytosis pathways (e.g. clathrin or caveolae- 
mediated/independent endocytosis, or micropinocyto-
sis) in PANC-1 cells as they do not show such saturable 
uptake. However, broader and more in-depth com-
parative studies are needed to conclude whether this 
preferential uptake holds for other PC cell lines, and 
that if the exosome-parent cell pairing is also important 
in selective uptake of tumour-derived exosomes in 
other cancer contexts. Specific protein(s) or lipid(s) 
component of the cell or exosomes that is important 
for the selective internalisation can then be determined 
to elucidate further understanding on the biochemical 
factors governing exosome uptake.
The doses used in the in vitro studies are in the 
range of 0.4–3.6 × 1010 particles for 30 K PC cells 
seeded in cell culture plate. For the in vivo study, it 
was assumed that there is a much higher number of 
cells (at least by an order of magnitude) in the 
implanted subcutaneous PC tumour than that from 
the 30 K cells used in vitro. Therefore, a higher dose 
of 8 × 1011 particles per animal was used to ensure 
a comparable amount of exosomes of EVs were 
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administered. This single in vivo dose corresponds to 
approximately 11 µg (in terms of protein amount). It 
was reported that a higher dose of 60 μg of PC cells- 
derived exosomes had no observable side effects on 
Balb/c and NOD.CB17-Prkdc scid/J mice [41], and 
similarly the dose used in this work also did not give 
rise to any adverse effects in the mice.
The preferential uptake of PANC-1 Exo by their parent 
PANC-1 cells was recapitulated in vivo, as demonstrated 
by the significantly higher uptake of the former in PANC-1 
tumours than that in the more vascularised B16-F10 
tumours (Figure 6) [42]. It is worth noting that although 
B16-F10 cells were predicted by the DoE modelling to 
show preferential uptake of self-B16-F10 Exo in vitro in 
this study, which was observed with actual experimental 
investigation in our previous work, preferential uptake by 
B16-F10 tumours was not observed in vivo in the same 
previous study [32]. It was described earlier that expression 
of CD47 on exosome membranes confers protection from 
clearance by circulating macrophages and therefore pro-
longs the circulation time of exosomes in vivo [5]. CD47 
expression was significantly higher on PANC-1 Exo than 
that on B16-F10 Exo (negligible expression) (Figure 1(d)). 
This suggests that exosome circulation time is an impor-
tant enabling factor for manifestation of preferential 
uptake of exosomes by self-tissue in vivo. This finding 
also highlights the importance of assessing the expression 
of CD47 on exosomes as a selection criteria for suitability 
of a particular exosome type to be used as in vivo drug 
nanocarriers. The preferential uptake of unmodified self- 
exosomes by PC cells is therefore desirable for applications 
as nanocarriers for therapeutic delivery against PC, but 
warrants investigation into the risk of such strategy being 
counter-productive in terms of treatment efficacy due to 
the implication of tumour-derived exosomes in promoting 
tumour progression and metastasis [43]. Treatment effi-
cacy in pre-clinical PC models using PC-derived exosomes 
as nanocarriers should also be correlated with the extent of 
tumour accumulation of the unmodified exosomes, to 
determine if endowment of active targeting ligands specific 
for certain surface proteins overexpressed in PC (e.g. αvβ6 
integrin) on the exosomes are required [44]. The click- 
chemistry-based surface labelling approach proposed in 
this study would serve as an excellent tool for such studies.
Conclusions
In this work, we have reported a novel yet simple, 
reliable and universal method to fluorescently label 
exosomes without prior engineering on parent cells 
for tracking and quantification of their intracellular 
uptake in vitro and in vivo. We have also demonstrated 
that DoE is a useful and reliable tool for a multivariable 
study design and prediction of important factors gov-
erning uptake of different exosome types by PC cells. 
This has enabled us to validate exosome dose and 
incubation time as important factors that can positively 
influence exosome uptake into PC cells regardless of 
their cell sources. We also reported the preferential 
in vitro uptake of self-exosomes in a PC context. This 
preferential uptake of self-exosomes by PC cells was 
also recapitulated in vivo, and that the expression of 
CD47 on the exosomes is crucial for the manifestation 
of such favoured uptake in vivo. Findings from this 
work would serve as the framework for future rational 
design of exosomes as nanocarriers for delivery of 
therapeutics against the different forms of PC and 
other cancer contexts.
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